SGLT2 Inhibitors for Heart Failure and Type 2 Diabetes
SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan
- Age
- 18 – 80
- Sex
- Any
- Trial phase
- Early Phase 1
- Study type
- Interventional
- Purpose
- Basic Science
- Participants needed
- 30 (estimated)
- Sponsor
- The University of Texas Health Science Center at San Antonio · Other
This trial is looking for people with type 2 diabetes and certain heart issues to study the effects of SGLT2 inhibitors. Participants will be monitored for their heart function and physical abilities.
You may be able to join if
- I have been diagnosed with type 2 diabetes
- I have Class II-III heart failure
- I am between 18 and 80 years old
- My body mass index (BMI) is between 23 and 38
- My blood pressure is 145/85 mmHg or lower
- My blood sugar level (HbA1c) is between 5.5% and 10%
- My kidney function (eGFR) is 30 ml/min or better
- I have a stable weight for the last 3 months
You may not be able to join if
- I have been treated with an SGLT2 inhibitor or GLP-1 RA
- I am pregnant, breastfeeding, or planning to become pregnant
- I am allergic to the study drugs or their ingredients
- I have cancer
- I currently use drugs or alcohol
- I cannot give written consent
- I have severe claustrophobia
- I have a metal implant that makes MRI impossible
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your EligibilityThe study team will examine the effects of SGLT2i (and SGLT2i-induced increases in plasma ketone concentrations) on skeletal muscle and cardiac ketone uptake, skeletal muscle bioenergetics, cardiopulmonary exercise capacity, and patient-reported functional outcomes.
Loading trial locations…